Sun Pharmaceuticals

Leading Access to Medicine Practices

No leading practice identified for this company. 

Changes Compared to Index 2008

• Sun Pharmaceuticals was not included in Access to Medicine Index 2008.
• Sun Pharmaceuticals is seeking to enter into exclusive licensing agreements and to extend its market presence further in Index Countries such as China and regions of South-East Asia and Africa.
• There is evidence that Sun Pharmaceuticals is increasing local research capabilities in India by permitting students to use the Sun Pharmaceuticals Advanced Research Centre (SPARC), one of its primary research facilities.

Suggested Areas for Improvement

• Sun Pharmaceuticals has not adopted a strategic and tailored approach to Index Country markets.
• Sun Pharmaceuticals' sales of its existing Index Disease-relevant products are limited to few Index Countries.
• Sun Pharmaceuticals does not participate in adaptive research for the Index Diseases targeting specific Index Country needs, in areas such as, fixed-dose combinations (FDCs) and heat-sensitive formulations. Due to the company's expertise in dosage form development and innovative drug delivery approaches, Sun Pharma should be well-positioned to carry out adaptive research for Index Disease-related products.